Navigation Links
Cell Therapeutics to Present at Upcoming Investor Conferences
Date:5/14/2013

SEATTLE, May 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the following upcoming investor conferences. 

UBS Global Healthcare Conference
Tuesday, May 21, 2013 at 2:30 p.m. Eastern Time in New York, NY

Jefferies 2013 Global Healthcare Conference
Tuesday, June 4, 2013 at 3:00 p.m. Eastern Time in New York, NY

The presentations will also be webcast live and available for replay after the presentation.  The webcast can be accessed at www.celltherapeutics.com.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
T: +1 206.272.4343
E: mgreer@ctiseattle.com

Ed Bell
T: +1 206.272.4345
E: invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
http://www.celltherapeutics.com/italiano
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
3. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
4. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
5. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
6. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
7. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
8. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
11. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Woo Young Lee of the Chemical Engineering and ... of Chemistry, Chemical Biology and Biomedical Engineering at ... NSF funding for their research entitled, "Evaporative Assembly ... is a reflection of the pioneering work being ...
... 20 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or ... that its Special Meeting of Shareholders held today, its shareholders, ... excluding Mr. Han, voted to approve the merger of Datong ... to the Agreement and Plan of Merger dated March ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing ... entered into a purchase agreement to sell $3.9 million of ... registered public offering.   , , ... Under the terms of the purchase agreement, PharmAthene will sell an aggregate ...
Cached Biology Technology:NSF funds infection-resistant orthopedic research 2Dragon Pharma shareholders approve merger and seek termination of listing on the OTCBB and TSX 2PharmAthene Announces $3.9 Million Registered Direct Offering 2PharmAthene Announces $3.9 Million Registered Direct Offering 3
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... about one per eight hundred births, Down syndrome - ... cause of intellectual disability. It results from a chromosomal ... copy of chromosome 21 (1% of the human genome). ... in the Department of Genetic Medicine and Development at ... in Nature , shed light on how the ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... African-American women who get breast cancer often get more aggressive ... women. But a Georgia State University researcher has found ... which would let their doctors customize their treatment. Ritu ... called HSET. Earlier studies have linked elevated levels of HSET ...
... 2013  DigitalPersona, Inc., a trusted partner for biometric ... ® FingerJet ® Recognition Engine matching ... of Standards and Technology (NIST) and the MINEX ... States Government,s  Personal Identity Verification (PIV) standards.  ...
... Dec. 10, 2013 Kurt H. Becker , the ... at the Polytechnic Institute of New York University (NYU-Poly), has ... Inventors (NAI).  Becker was chosen by ... facilitating outstanding inventions that have made a tangible impact on ...
Cached Biology News:DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 2Kurt H. Becker Named a Fellow of the National Academy of Inventors 3
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains, Aga1 and Aga2, to display recombinant ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
Biology Products: